Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers

被引:147
作者
Lin, HK
Hu, YC
Yang, L
Altuwaijri, S
Chen, YT
Kang, HY
Chang, CS [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA
[4] Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA
[5] Chang Gung Univ, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan
关键词
D O I
10.1074/jbc.M300676200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The phosphatidylinositol 3- kinase ( PI3K)/ Akt pathway controls several important biological functions, such as cell growth regulation, apoptosis, and migration. However, the way in which PI3K/ Akt controls androgen receptor ( AR)- mediated prostate cancer cell growth remains unclear and controversial. Here, we demonstrate that the PI3K/ Akt pathway regulates AR activity in a cell passage number- dependent manner. Specifically, PI3K/ Akt pathway can suppress AR activity in androgen- dependent LNCaP cells with low passage numbers. In contrast, it can also enhance AR activity in LNCaP cells with high passage numbers. Furthermore, we also demonstrate that insulin- like growth factor- 1 can activate the PI3K/ Akt pathway that results in the phosphorylation of AR at Ser(210) and Ser(790). The consequence of these events may then change the stability of AR protein. Together, our results demonstrate that the PI3K/ Akt pathway may have distinct mechanisms to modulate AR functions in various stages of prostate cancer cells and that a combined therapy of antiandrogens and anti- PI3K/ Akt inhibitors may be worth considering as a future therapeutic approach to battle prostate cancer.
引用
收藏
页码:50902 / 50907
页数:6
相关论文
共 18 条
[1]  
Carson JP, 1999, CANCER RES, V59, P1449
[2]   The multiple roles of PTEN in tumor suppression [J].
Di Cristofano, A ;
Pandolfi, PP .
CELL, 2000, 100 (04) :387-390
[3]   Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 [J].
Fang, SY ;
Jensen, JP ;
Ludwig, RL ;
Vousden, KH ;
Weissman, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8945-8951
[4]   PI3K: Downstream AKTion blocks apoptosis [J].
Franke, TF ;
Kaplan, DR ;
Cantley, LC .
CELL, 1997, 88 (04) :435-437
[5]   Androgen receptor phosphorylation - Regulation and identification of the phosphorylation sites. [J].
Gioeli, D ;
Ficarro, SB ;
Kwiek, JJ ;
Aaronson, D ;
Hancock, M ;
Catling, AD ;
White, FM ;
Christian, RE ;
Settlage, RE ;
Shabanowitz, J ;
Hunt, DF ;
Weber, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (32) :29304-29314
[6]   Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression [J].
Graff, JR ;
Konicek, BW ;
McNulty, AM ;
Wang, ZJ ;
Houck, K ;
Allen, S ;
Paul, JD ;
Hbaiu, A ;
Goode, RG ;
Sandusky, GE ;
Vessella, RL ;
Neubauer, BL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (32) :24500-24505
[7]   Androgen receptor (AR) coregulators: An overview [J].
Heinlein, CA ;
Chang, CS .
ENDOCRINE REVIEWS, 2002, 23 (02) :175-200
[8]   Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 [J].
Honda, R ;
Tanaka, H ;
Yasuda, H .
FEBS LETTERS, 1997, 420 (01) :25-27
[9]   Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor [J].
Hu, YC ;
Shyr, CR ;
Che, WY ;
Mu, XM ;
Kim, E ;
Chang, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (37) :33571-33579
[10]   Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells [J].
Li, PF ;
Nicosia, SV ;
Bai, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :20444-20450